Please login to the form below

Not currently logged in
Email:
Password:

Huntingdon's disease

This page shows the latest Huntingdon's disease news and features for those working in and with pharma, biotech and healthcare.

Ionis and Roche gain PRIME status for Huntingdons disease candidate

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval. Ionis and Roche’s pipeline drug for Huntingdon’s disease has been granted special ‘PRIME’ status by the European Medicines Agency (EMA). ... s disease to regulatory approval faster.

Latest news

  • EMA hands UniQure orphan status first in Huntington's EMA hands UniQure orphan status first in Huntington's

    Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure’s candidate fit the bill, not least because there are no currently approved

  • Roche signs Parkinson's deal with Prothena Roche signs Parkinson's deal with Prothena

    Antibody development agreement is worth up to $600m. Roche has upped its efforts in Parkinson's disease by agreeing to research new antibodies with the US biotech Prothena. ... This technology was also a key aspect of a recent deal with Isis to tackle

  • Roche and Isis in $392m deal to research drugs for brain disorder Roche and Isis in $392m deal to research drugs for brain disorder

    The unmet medical need for Huntingdon's disease is compounded by its severity,  with patients enduring progressive loss of both mental faculties and physical control. ... foundation exclusively dedicated to the development of therapies that slow the

  • Bouncing back

    The deal should speed up new treatments for Huntingdon's disease, Parkinson's disease and for strokes. ... attention to incidents of vision loss among patients taking GSK's Levitra, Pfizer's Viagra and Lilly's Cialis.

  • Malcolm's Market Eye: 7 to 13 July 2007

    The market for ReNeuron's treatment is large with some 12m stroke survivors in Japan, the US and the EU, with nearly one third needing continual nursing care. ... ReNeuron is also focusing on inherited Huntingdon's disease and type 1 diabetes needing

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics